SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries informs about press release

24 Apr 2025 Evaluate
Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release by the company (together with its subsidiaries / associate companies, ‘Sun Pharma’) and Israel-based Moebius Medical about the announcement of publication of two articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI), highlighting MM-II, a novel nonopioid product for the treatment of symptomatic knee osteoarthritis.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Inds. Share Price

1874.20 26.90 (1.46%)
11-May-2026 12:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.20
Dr. Reddys Lab 1295.65
Cipla 1314.50
Zydus Lifesciences 943.65
Lupin 2267.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×